Envarsus (LCP-tacrolimus) is a once daily tacrolimus formulation that increases adherence and decreases side effects in children with organ transplants. Recently Veloxis, the drug company who produces and sells Envarsus, restricted the use of the Envarsus copay card to patients 18 years old and up. This has resulted in pediatric patients transitioning back to IR twice daily tacrolimus, negatively impacting patient care. We are working with leadership groups (CHA and PPA) to ask Veloxis to reverse this decision.